目的探讨小剂量灯盏花素治疗胎儿生长受限(FGR)的临床疗效和安全性。方法将170例FGR患者分为3组,常规治疗组42例,予能量合剂和复方氨基酸500 ml静滴;灯盏花素组77例,将灯盏花素10 mg溶于10％葡萄糖注射液500 ml中静滴,4～6 h滴完,其余治疗同常规治疗组;复方丹参组51例,将丹参16 ml加入低分子右旋糖酐500 ml中静滴,其余治疗同常规治疗组。另有47例FGR患者未行药物治疗(对照组)。治疗前后监测胎儿生长情况及脐血流变化,同时监测孕妇肝肾功能、血浆内皮素水平。记录新生儿情况并进行随访。结果(1)灯盏花素组与复方丹参组胎儿双顶径、股骨长、头围、腹围增大均优于常规治疗组和对照组(P< 0．01)。(2)灯盏花素组与复方丹参组脐动脉血流S／D值分别为2．52±0．56、2．41±0．53,均低于对照组的2．91±0．54(P<0．05)。(3)灯盏花素组新生儿出生1分钟Apgar评分8．96’±0．57’,20项神经行为评分39．21±2．45分,出生体重3．29±0．28 kg,出生身长50．42±1．69 cm,出生头围34．23±0．57 cm,均较其他三组大(P< 0．01);胎龄39．85±1．52周,也长于对照组(P(0．01)。(4)灯盏花素组足月小样儿1例(1．29％),Apgar评分<7’3例(3．89％),新生儿20项神经行为评分<36分4例(5．19％),发生率均低于对照组(P<0．01)。(5)灯盏花素组新生儿出生后42天体重5．09±0．31 kg,身长52．43±1．39 cm,头围36．27±0．66 cm,组间比较均有极显著性差异(P<0．01)。(6)各组孕妇治疗前后肝肾功能、血浆内皮素值及新生儿脐带血查心肝肾功能比较,均无显著性差异(P>0．05)。结论灯盏花素用于治疗。FGR可改善胎盘血流,使胎儿体重增加,减少足月小样儿的发生,改善围产儿的预后,且对母婴都较安全。 Objective To investigate the clinical efficacy and safety of small dose Breviscapine in the treatment of fetal growth restriction (FGR). Methods 170 cases of FGR patients were divided into three groups, 42 cases in the conventional treatment group were treated with 500 ml intravenous drip of energy mixture and compound amino acid; Breviscapine group 77 cases, the breviscapine 10 mg dissolved in 10% glucose injection 500 ml Intravenous drip, 4 ~ 6 h drop finished, the rest of the treatment with the conventional treatment group; compound Salvia group 51 cases, the Salvia 16 ml added low molecular weight dextran 500 ml intravenous infusion, the rest of the treatment with the conventional treatment group. Another 47 cases of FGR patients without medication (control group). Before and after treatment to monitor fetal growth and changes in umbilical blood flow, while monitoring of liver function in pregnant women, plasma endothelin levels. Record newborns and follow up. Results (1) Breviscapin group and compound Danshen group fetal biparietal diameter, femur length, head circumference, abdominal circumference were better than conventional treatment group and control group (P <0.01). (2) The S / D values ​​of umbilical artery blood flow between Breviscapine group and Compound Salvia Miltiorrhiza group were 2.52 ± 0.56 and 2.41 ± 0.53, both lower than that of the control group (2.91 ± 0.54) (P <0.05). (3) Breviscapine group neonatal Apur score of 8.96 ± 0.57 at 1 minute, 20 neurobehavioral score of 39.21 ± 2.45, birth weight of 3.29 ± 0.28 kg, birth Body length was 50.42 ± 1.69 cm and birth head circumference was 34.23 ± 0.57 cm, all of which were larger than the other three groups (P <0.01); gestational age was 39.85 ± 1.52 weeks, Group (P (0.01). (4) Breviscapine full-term small sample in 1 case (1.29%), Apgar score <7’3 cases (3.89%), neonatal 20 neurological behavior score <36 points in 4 cases (5.19%), the incidence was lower than the control group (P <0.01). (5) Breviscapine group 42 days after birth, weight 5.09 ± 0.31 kg, Body length was 52.43 ± 1.39 cm and head circumference was 36.27 ± 0.66 cm. There was significant difference between the two groups (P <0.01). (6) Before and after treatment, the liver and kidney function, (P> 0.05) .Conclusion Breviscapine is used for the treatment.FGR can improve the blood flow of the placenta, make the fetus gain weight and reduce the weight of the fetus Full-term baby’s appearance, to improve the prognosis of perinatal children, and more safe for both mother and child.